National Institute of Aging, Alzheimer’s Association (NIA-AA) had made it clear that, regardless of cognitive symptoms, AD could be determined only based on abnormal Aβ and tau protein deposition (Jack et al., 2018). This evidence concerns the gene MAPT and Alzheimer disease.